All studies
Ongoing, recruitingPhase I and Phase II (Integrated)- OtherInterventional
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY)
At a glance
Status
Ongoing, recruiting
Phase
Phase I and Phase II (Integrated)- Other
Sponsor
Akamis Bio Limited
Enrolment target
85
Start
12 Jun 2023
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (2)
- —Belgium
- —Spain
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.